Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 10, 2016. The document serves as a transaction notification regarding the acquisition of ordinary shares by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them under the Company's ShareReward Plan.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share transactions.
| Transaction Date | Instrument | Price per Share | Total Volume | Exchange |
|---|---|---|---|---|
| November 9, 2016 | Ordinary Shares (25 pence each) | £15.9267 | 14 to 16 shares per individual | London Stock Exchange (XLON) |
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It reports routine equity compensation transactions executed on November 9, 2016.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of insider trading activity.
Important Facts for Investors
- Transaction Type: All reported transactions were acquisitions of ordinary shares under the ShareReward Plan, consisting of partnership shares and matching shares.
- Participants: Transactions were executed by senior executives including Sir Andrew Witty (CEO), Ms E Walmsley (CEO Designate), Mr S Dingemans (CFO), and other senior officers.
- Volume: Individual transaction volumes were minimal, ranging from 14 to 16 shares per executive.
- Price: All shares were acquired at a uniform price of £15.9267.
- Financial Data: This filing does not contain financial performance data; investors should refer to Form 20-F or quarterly reports for revenue and earnings information.